BioSpace News Archive

Stevanato Group S.p.A., a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced its financial results for the third quarter of 2022.

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Mallinckrodt plc (NYSE American: MNK) (“Mallinckrodt” or the “Company”), a global specialty pharmaceutical company, today reported results for the third quarter ended September 30, 2022.1

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” “our,” “us,” or “we”), a clinical-stage biopharmaceutical company, today announced financial results for the third quarter of 2022 and provided an update on the Company’s business operations and clinical development programs.

Asensus Surgical, Inc. today announced that the Dr. von Hauner Children’s Hospital at the Ludwig Maximilians University Munich (“LMU”), has entered into an agreement to lease and utilize a Senhance® Surgical System.

HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB) today announced that data will be presented at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (“SITC”) from an ongoing Phase 1 clinical trial to evaluate HCW9218 in patients with chemo-refractory/chemo-resistant solid tumors, conducted by the Masonic Cancer Center, University of Minnesota.

Orchard Therapeutics, a global gene therapy leader, announced that members of the management team will present at the following investor conferences.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) today announced that Kimberly Blackwell, MD, Chief Executive Officer of Zentalis, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022 at 1:15 p.m. ET.

IGM Biosciences, Inc., a clinical-stage biotechnology company focused on creating and developing IgM antibodies, announced that Fred Schwarzer, Chief Executive Officer, will participate in fireside chats at three upcoming investor conferences.

Alladapt Immunotherapeutics Inc. announced that Ashley Dombkowski, Chief Executive Officer of Alladapt, will participate in two upcoming investor conferences in November.